Zura Bio completes enrollment in two Phase 2 tibulizumab trials; cash $205.1M

Zura Bio Ltd

2026-Q2 EPS reported -$0.42

TibuSHIELD (hidradenitis suppurativa) enrolled 247 participants, exceeding target; topline data Q4 2026.
TibuSURE (systemic sclerosis) enrolled 91 participants, exceeding target; topline data H1 2027.
New indication: plans Phase 2 NEXUS-PMR for polymyalgia rheumatica by year-end 2026.
Q2 2026 net loss $26.3M ($0.21/share) vs $16.0M ($0.17/share) in Q2 2025; R&D expenses $20.7M vs $8.7M.
Cash and equivalents $205.1M expected to fund operations through at least end of 2028.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.